Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E17.55 EPS (ttm)9.77 Insider Own0.20% Shs Outstand751.00M Perf Week-1.63%
Market Cap128.80B Forward P/E13.74 EPS next Y12.48 Insider Trans-3.61% Shs Float747.47M Perf Month0.28%
Income7.43B PEG2.07 EPS next Q2.80 Inst Own81.20% Short Float1.08% Perf Quarter9.22%
Sales22.47B P/S5.73 EPS this Y35.20% Inst Trans-0.54% Short Ratio2.79 Perf Half Y17.02%
Book/sh40.12 P/B4.27 EPS next Y9.84% ROA10.10% Target Price191.00 Perf Year12.73%
Cash/sh46.65 P/C3.68 EPS next 5Y8.48% ROE25.90% 52W Range126.96 - 176.64 Perf YTD7.71%
Dividend4.00 P/FCF21.52 EPS past 5Y13.60% ROI12.50% 52W High-2.90% Beta0.88
Dividend %2.33% Quick Ratio3.70 Sales past 5Y7.60% Gross Margin81.40% 52W Low35.09% ATR2.61
Employees17900 Current Ratio4.00 Sales Q/Q5.90% Oper. Margin40.70% RSI (14)56.62 Volatility1.67% 1.45%
OptionableYes Debt/Eq1.10 EPS Q/Q14.90% Profit Margin33.10% Rel Volume0.87 Prev Close171.51
ShortableYes LT Debt/Eq0.93 EarningsJul 27 AMC Payout36.30% Avg Volume2.90M Price171.51
Recom2.40 SMA20-0.54% SMA504.62% SMA20010.70% Volume0 Change0.00%
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Aug-29-16 04:46PM  [$$] Regeneron Can Generate Big Returns for Investors at Barrons.com
09:33AM  Regeneron/Sanofi Present Positive Phase III Praluent Data
09:00AM  Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy PR Newswire
08:01AM  3 Trades for an Upward Surprise Move in Amgen
02:00AM  New Repatha® (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016 PR Newswire
Aug-28-16 07:07AM  Time to Shift Your Focus
Aug-27-16 09:12AM  These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year at Motley Fool
Aug-26-16 02:21PM  What Tidings From the Tetons? Long-Awaited Yellen Speech Today
01:12PM  [$$] Don't Expect an Amgen Breakup at Barrons.com
10:05AM  Analyzing Goldman Sachss Stock Picks with Growing Dividends
09:38AM  Coverage initiated on Amgen by Gabelli & Co
08:00AM  Mylan offers price plan to help patients but its programs are still short on details at MarketWatch
Aug-25-16 03:30PM  ADXS: Multiple Progresses Have Been Made
09:27AM  Amgen's Shameful Silence Covers Up Reasons for FDA Drug Rejection
09:04AM  Will Teva Pharmaceutical Strengthen Specialty Pipeline in 3Q16?
08:40AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
08:28AM  Amgen Gets CRL for Secondary Hyperparathyroidism Drug
Aug-24-16 06:50PM  [$$] FDA Rejects Amgen Hormonal-Imbalance Treatment at The Wall Street Journal
06:03PM  Amgen Provides Update On Status Of Parsabiv (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA) PR Newswire
12:59PM  Top trades for the 2nd half: Lending Club, Amgen & more
11:04AM  Litigation Has Teva Pharmaceuticals Copaxone 40 mg All Tied Up
11:04AM  Imbruvica Continues to Report Better-than-Expected Sales in 2016
10:04AM  How Humira-Related Uncertainty Has Affected AbbVies Valuations
Aug-23-16 05:04PM  Why AstraZeneca Reported Negative Growth in 2Q16
02:31PM  Why Bernstein Thinks Inflation May Have Bottomed Out
02:04PM  What Are Analysts Recommendations for AbbVie in 2016?
12:59PM  Top trades for the 2nd half: CVS, SQ & more
12:09AM  [$$] Pfizers Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
Aug-22-16 12:22PM  [$$] Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions at The Wall Street Journal
09:04AM  Understanding the Growth Drivers behind Horizons Rheumatology Business Unit
09:00AM  New Data Add To Understanding Of Repatha® (Evolocumab) In Multiple Patient Populations PR Newswire
Aug-21-16 11:41AM  3 Reasons Medivation Is the Juiciest Target in Biotech at Motley Fool
Aug-19-16 04:14PM  AMGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhi
08:08AM  3 Cheap Dividend Stocks You Can Buy Right Now at Motley Fool
07:00AM  No Pain, Potential for Lots of Gain at Morningstar
Aug-18-16 09:05AM  Investment-Grade Bond Fund Flows Rose Slightly Last Week
Aug-17-16 03:49PM  Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data
11:04AM  What Do Analysts Estimate for Merck?
09:07AM  Westpac Banking Issued the Most High-Grade Bonds Last Week
08:49AM  Investment-Grade Corporate Bond Issuance Fell Last Week
08:21AM  Better Buy: Amgen Inc. vs. Biogen at Motley Fool
Aug-16-16 01:07PM  Coherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN) at Insider Monkey
11:00AM  Amgen, Sanofi Cholesterol Drugs Not Cost-Effective, Study Says at Bloomberg
Aug-15-16 11:58AM  Biotech Stocks: The Rebirth of the Bull? at Barrons.com
Aug-12-16 04:31PM  Third Point adds Facebook position; eliminates Amgen, Kraft at MarketWatch
11:41AM  Prices for These 4 Top-Selling Prescription Drugs Have More Than Doubled Since 2010 at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
06:30AM  Analysts: Gilead Should Divide Itself and Conquer
12:12AM  [$$] Biotechs Resurgence May Cost Big Pharma at The Wall Street Journal
Aug-11-16 05:30PM  Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
11:37AM  [$$] Biotech's Resurgence May Cost Big Pharma at The Wall Street Journal
11:19AM  4 Reasons Amgen, Inc. Shareholders Netted a 13% Gain in July at Motley Fool
Aug-10-16 03:34PM  Siegel called the market rally here's what he sees happening next at CNBC
12:04PM  Pfizers Business Segments and Their Performance
08:58AM  Amgen Inc. -- Moody's assigns Baa1 to Amgen's new notes at Moody's
08:50AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Aug-09-16 10:49AM  Biotech Stocks: Blame Gilead? at Barrons.com
06:15AM  In change of tack, UK agency backs Amgen virus-based cancer drug
Aug-08-16 04:03PM  Stocks Retreat From Records as Health Care Slumps
02:50PM  Stocks Fall as Health Care Selloff Counters Energy Rally
01:46PM  How Did Regenerons Revenue and Earnings Look in 2Q16?
08:07AM  Barron's: How To Find Safe 5% Yields
Aug-07-16 09:15AM  Lets Get Real!
Aug-06-16 12:26AM  [$$] AbbVie Files Patent Suit Over Amgens Copy of Humira at The Wall Street Journal
Aug-05-16 04:48PM  [$$] AbbVie Sues Amgen Over Humira at The Wall Street Journal
02:38PM  AbbVie (ABBV) Stock Up, Sues Amgen to Block Humira Copycat
11:32AM  AbbVie Sues Amgen to Fend Off Copy of Blockbuster Humira
Aug-04-16 06:42PM  Healthcare Dividend Growth Stocks: Part 1
02:37PM  ETFs with exposure to Amgen, Inc. : August 4, 2016
01:04PM  AMGEN INC Financials
11:03AM  Regeneron: EPS Beat and 21% Revenue Growth Not Enough to Impress; Shares Down 4.4% at Barrons.com
10:00AM  Amid Biotech Rally, Investors Show Jitters
06:56AM  Kite (KITE) Q2 Earnings: What's in Store for the Stock?
Aug-03-16 12:30PM  Time to buy biotech?
11:04AM  Inside Amgens Analyst Recommendations for 2016
09:04AM  Anti-Inflammation Drug Enbrel Boosts Amgens Revenue in 2Q16
08:07AM  Pro: Biogen did not put 'for sale' sign out
12:38AM  [$$] CVS Drops Coverage of 2 Branded Biotech Drugs in Favor of Copies at The Wall Street Journal
Aug-02-16 06:18PM  [$$] CVS Drops Coverage of 2 Branded Biotech Drugs in Favor of Copies at The Wall Street Journal
05:15PM  Biogen: Deal or no deal?
04:25PM  CVS Health Takes "An Audacious Step" With 2017 Drug Formularies at Barrons.com
12:35PM  Why Advaxis Shares Could More Than Double, Even After the Amgen Deal at 24/7 Wall St.
11:42AM  Amgen, Inc. :AMGN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 2, 2016
11:05AM  Amgen Continued to Manage Life Cycles of Its Mature Brands in Q2
11:05AM  Analyst Recommendations for Vertex Pharmaceuticals after 2Q16 Earnings
10:21AM  Amgen, Regeneron Forge New, Separate Cancer Immunotherapy Pacts
09:05AM  Factors That Will Determine Repathas Future Commercial Success
08:42AM  Advaxis stock jumps 28% on Amgen immunotherapy agreement at MarketWatch
08:00AM  Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration PR Newswire
Aug-01-16 05:05PM  What's Driving The Biotech Stock Rally? And Will It Last?
04:04PM  Can Amgen Break Out?
02:51PM  These Top Biotech Stocks Are Leading The Industry's Rebound
12:33PM  Biotech bounce
12:00PM  Dividends in danger?
11:08AM  Sales from This Amgen Product Helped the Companys Q2 Earnings
10:04AM  GlaxoSmithKlines Revenue Trend in 2Q16
09:25AM  RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains at 24/7 Wall St.
09:09AM  These Drugs Were Key Growth Drivers for Amgens Revenue in 2Q16
05:26AM  With latest swing, Peninsula biotech tries to double up Lou Gehrig's disease at bizjournals.com
Jul-29-16 04:50PM  AMGEN INC Files SEC form 10-Q, Quarterly Report
Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc.; and Advaxis, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM
de Carbonnel FrancoisDirectorAug 31Sale153.845,000769,19215,150Sep 02 07:46 PM